Does Cardinal Health's Acquisition Of Zuellig Pharma Signal China's Intent To Allow More Foreign Investment?
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. wholesaler's entry could signal the Chinese government is willing to approve foreign ownership in health care industries, such as drug distribution, that historically have been reserved for domestic players.
You may also be interested in...
Cardinal Eyeing Further Acquisitions In China
Cardinal Health’s recent acquisition of Zuellig Pharma China (Yong Yu in Chinese) likely will not be the last China-based distributor the U.S. wholesaler will pick up, according to company CFO Jeff Henderson.
Cardinal Eyeing Further Acquisitions In China
Cardinal Health’s recent acquisition of Zuellig Pharma China (Yong Yu in Chinese) likely will not be the last China-based distributor the U.S. wholesaler will pick up, according to company CFO Jeff Henderson.
China's Largest Private Drug Distributor, Jointown, Seeks Initial Public Offering In Shanghai
SHANGHAI - To compete with the country's largest drug distributor SinoPharm, China's third-ranked Jointown recently filed for an initial public offering in Shanghai to raise roughly RMB 899.8 million ($135.4 million) to expand a distribution network in seven key regions across China